Cardiac Death Articles & Analysis
19 news found
The procedure was performed by cardiac electrophysiologist James D. Allred. M.D. and vascular surgeon Wells Brabham, M.D.. at The Moses H. ...
ByCVRx
Levels < 86 ng/mL included among other things a lower risk of cardiovascular events (such as ventricular tachycardia, ventricular fibrillation, sudden cardiac death), improved cardiac function, and low fatty infiltration in the heart. ...
CCTA delineation of the extent of atherosclerosis, coupled with FFR-CT to assess ischemia and plaque composition analysis to assess lesion vulnerability, should comprehensively risk stratify patients with suspected and established coronary artery disease, and enable development of novel approaches and therapies to prevent acute coronary syndromes, myocardial infarction and ...
ByElucid
Infection can lead to chronic disease lasting decades, with a higher risk of death due to cardiac or digestive system impairment; up to one third of infections result in debilitating symptoms, while the remainder are asymptomatic. ...
Long considered a “holy grail” of medicine, the ability to identify vulnerable plaque by any modality, invasive or otherwise marks a landmark capability for patients that have historically been at risk for adverse events such as sudden cardiac death. Results showed classification measured against ex vivo data was more than sufficient for clinical use ...
ByElucid
” VT and ventricular fibrillation are important causes of sudden cardiac death, accounting for as many as 450,000 annual deaths in the US alone. Implantable cardiac defibrillators reduce the incidence of death in patients with arrhythmias, but are not curative, and can contribute to reduced quality of life ...
” The second benefit, as shown by the data presented at SCCT, is that on the basis of those tissue distributions, the study investigators were able to anticipate which patients are at risk for sudden cardiac death, which has long been considered a holy grail of modern medicine because then doctors can make treatment decisions aimed at reducing that ...
ByElucid
Arrhythmias affect millions of Americans every year, and the most dangerous arrhythmia, ventricular tachycardia, can cause sudden cardiac death, affecting approximately a half million people annually in the United States[1]. ...
Food & Drug Administration (FDA) approved Thermedical’s degassed saline for usewith itsSaline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter,currently being studiedfor the treatment of ventricular tachycardia(VT), a leading cause of sudden cardiac death worldwide. ...
The system uses a new means of biological heat to precisely deliver ablation therapy to the heart.VT is a leading cause of sudden cardiac death worldwide – an event that kills roughly 325,000 U.S. adults each year. ...
Ventricular tachycardia, which is an abnormally rapid heart rhythm, is a leading cause of sudden cardiac death worldwide. Sudden cardiac death kills 325,000 U.S. adults annually, more than any other natural ...
WALTHAM, Mass., May 8, 2020 - Thermedicak a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today. Called the Saline Enhanced Radiofrequency ...
The Primary endpoint of the EluNIR-HBR study is a composite of cardiac death, myocardial infarction or stent thrombosis at 1 year (ARC definite and probable). ...
ByMedinol
In September 2019, Orchestra BioMed announced CE mark approval for its Moderato® implantable pulse generator system that delivers BackBeat Cardiac Neuromodulation Therapy™ (CNT™) for the treatment of hypertension. ...
The presentations will also feature BackBeat™ Cardiac Neuromodulation Therapy for which recently presented double-blind, randomized clinical results demonstrated a statistically significant reduction of 24-hour ambulatory systolic blood pressure. ...
Its current product pipeline was organically developed and features Virtue® Sirolimus-Eluting Balloon (SEB) for the treatment of artery disease, the leading cause of death worldwide, and BackBeat Cardiac Neuromodulation Therapy™ (CNT™) for the treatment of hypertension, the leading contributing risk factor for death worldwide. ...
Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control High responder rate despite 88.5% of treated patients having isolated systolic hypertension (ISH) Primary safety endpoint achieved with no difference in major cardiac ...
EndoLogic announced that the FDA accepted the cardiac safety trial for renzapride in patients with gastroparesis. That study demonstrated no evidence of QTc prolongation in the EKG findings. ...
Immediately after, the team was called out again: another case of cardiac arrest, this time a woman in her 30s. Once again, Frost was powerless to save her life. ...